Madrigal Pharmaceuticals initiated with an Outperform at SVB Leerink. SVB Leerink analyst Pasha Sarraf initiated Madrigal Pharmaceuticals with an Outperform rating and $165 price target, telling investors in a research note that MGL-3195 is “chasing a dream” of targeting thyroid signaling with a beta-selective agonist. Sarraf says he is positive on the immunology sector with its diverse indications, continuous innovation, and deep expertise, and is looking long for opportunities in challenging immuno-metabolism and metabolism sectors, in areas like NASH, obesity and diabetes.
https://thefly.com/landingPageNews.php?id=2868723
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.